about
Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndromePharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndromeEvaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility SocietiesEffects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans.Practical pointers for grappling with GERD. Heartburn gnaws at quality of life for many patients.Stomach dysfunction in diabetes mellitus: emerging technology and pharmacologyProlonged idiopathic gastric dilatation following revascularization for chronic mesenteric ischemia.Diagnosing gastroesophageal reflux disease.Methods for the assessment of small-bowel and colonic transit.Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study.A novel technique for bedside anorectal manometry in humans.Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders.Secretory diarrhea and hypokalemia associated with colonic pseudo-obstruction: A case study and systematic analysis of the literature.A Pilot Study of the Effect of Daikenchuto on Rectal Sensation in Patients with Irritable Bowel SyndromeEffects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome.Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine.A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research.Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects.Optimizing analysis of stable isotope breath tests to estimate gastric emptying of solids.The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006.Methods for measurement of gastric motility.Gastric emptying.Polymorphisms of 5-HTT LPR and GNβ3 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial.Prevalence, trends, and risk factors for fecal incontinence in United States adults, 2005-2010.Endoscopic "no hole" full-thickness biopsy of the stomach to detect myenteric ganglia.Endoscopic full-thickness biopsy of the gastric wall with defect closure by using an endoscopic suturing device: survival porcine study.Innovative gastric endoscopic muscle biopsy to identify all cell types, including myenteric neurons and interstitial cells of Cajal in patients with idiopathic gastroparesis: a feasibility study (with video).Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans.Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans.Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus.Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD).Effects of Antidepressants on Gastric Function in Patients with Functional Dyspepsia.Gastric Motor Dysfunction in Patients With Functional Gastroduodenal Symptoms.Effects of naloxegol on whole gut transit in opioid-naïve healthy subjects receiving codeine: A randomized, controlled trial.Expanding submucosal endoscopy with applied knowledge.Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial.Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.Evaluation of Patients with Suspected Gastroparesis
P50
Q24684839-21B9BD68-B9F3-469F-8DBD-3743F3359CA1Q28244460-5536D88A-DE14-4E8D-9F37-E258A92A846DQ28300067-DACDE2FE-2892-41D0-82C8-7FCA06F0B035Q33426587-6EED7BCD-66BC-4015-BC9E-E779BEF9ED62Q33665142-EF0918C6-DD12-4CDD-9412-0D9A9A5439C7Q33674557-0F8A3E28-DD72-4878-AE79-4D6193947C6AQ33813450-013504A2-2D2F-4F1B-8ED8-3FD37BA09A22Q34129710-AB604384-DC2C-4279-84E6-AACDA017BEF8Q35724278-AFA27844-2FD9-46C8-9EC2-F4E2A282D4CCQ35893549-F6FBD28F-45E9-4121-8161-C5F41F86E6CAQ36096062-B5225ED0-3210-422D-BA1C-8675A591352EQ36319562-25BBB205-0D0C-4951-94BC-B716E6D951BCQ36392505-3CB176CB-EAC0-4E75-A2E9-E56518BFB1B4Q36426039-BA1B6825-EBF2-4E06-9CCC-D122A883E05EQ36970524-A9E345BC-19E8-4258-89F9-32937F523B69Q37009041-FB600DCB-4881-463E-A9CE-2EF2E47AF749Q37086144-6CE285E8-EA97-4490-B353-688F1C66D822Q37100282-8522B98A-DD5B-43DE-82BD-4D6E397F7CE8Q37246547-7F7A4737-8FDF-4B82-8DE0-FEDAEAF0E219Q37250932-13394918-87D4-4040-9FF1-C4AA21951802Q37369680-C9396BD6-41E9-47B6-B42F-51651CF2D077Q37460160-BD28E459-BC79-4F3E-A1F2-297D5D029660Q38909322-FD4696B7-A412-4FF6-A35C-0B6B1817477AQ39374136-B77394B2-3CEE-4245-BB4F-D4152B37F34EQ40125507-5F20A9B3-8205-45C4-83B3-D61AEE5B360CQ41162168-87ACB63D-8BE1-4B17-AD9E-DE47A54F9E5FQ41516260-670F3BD7-7681-4020-891C-165AA4374D3AQ43340470-BD73C69B-13B2-49BD-83CE-07325907694EQ43797541-929FE655-75CF-45DD-8DBF-59CCA12368D5Q43970895-8CEA95A8-B5D0-4E2A-BF31-2D30DF1F07FEQ46972497-9DB8F5CA-D510-4206-9510-19834189E077Q47283483-F3457C20-A9B2-4BBC-9CDF-90C90457535CQ47775655-EBC7C98B-D9DB-4080-A44A-20CF9E8EB683Q48099588-2B460D18-FBC2-4057-A6B1-6CE1294C4E22Q50469088-33BB53B9-BA74-400E-A724-CEAFE9EFC265Q51022617-A761F164-2907-4354-9317-23142542B7C9Q51751566-99379D87-69B0-4B4E-8073-65CCF7B76AB7Q58543133-FCD816C7-77B4-4485-984C-9C7C7ED129DC
P50
description
Amerikaans onderzoeker
@nl
forsker
@nb
researcher
@en
հետազոտող
@hy
name
Lawrence A. Szarka
@ast
Lawrence A. Szarka
@da
Lawrence A. Szarka
@de
Lawrence A. Szarka
@en
Lawrence A. Szarka
@es
Lawrence A. Szarka
@fr
Lawrence A. Szarka
@nb
Lawrence A. Szarka
@nl
Lawrence A. Szarka
@nn
Lawrence A. Szarka
@sl
type
label
Lawrence A. Szarka
@ast
Lawrence A. Szarka
@da
Lawrence A. Szarka
@de
Lawrence A. Szarka
@en
Lawrence A. Szarka
@es
Lawrence A. Szarka
@fr
Lawrence A. Szarka
@nb
Lawrence A. Szarka
@nl
Lawrence A. Szarka
@nn
Lawrence A. Szarka
@sl
altLabel
Lawrence A Szarka
@en
Lawrence Szarka
@nb
prefLabel
Lawrence A. Szarka
@ast
Lawrence A. Szarka
@da
Lawrence A. Szarka
@de
Lawrence A. Szarka
@en
Lawrence A. Szarka
@es
Lawrence A. Szarka
@fr
Lawrence A. Szarka
@nb
Lawrence A. Szarka
@nl
Lawrence A. Szarka
@nn
Lawrence A. Szarka
@sl
P21
P31
P496
0000-0002-9894-5824